U.S. market Open. Closes in 2 hours

GRTX | Galera Therapeutics, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for GRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is desperately bad and Health is very weak.

Valuation (5%)

Company Industry
P/E Ratio (TTM) -0.13 -23.37
PEG Ratio (TTM) 0.00 -7.10
P/S Ratio (TTM) 28.43 44.34
P/B Ratio (TTM) -0.02 33.03
P/FCF Ratio (TTM) -0.25 -7.73
Price to 5YR AVG Earnings Ratio -0.02 -7.08
Price to 5YR AVG FCF Ratio -0.05 -13.02

Profitability (35%)

Company Industry
ROA (TTM) -220.35% -15.67%
ROE (TTM) 14.34% 27.44%
Net Profit Margin (TTM) -22,287.50% -627.99%
ROIC 5YR AVG 98.82% -4.84%

Growth (25%)

4QTR AVG 3YR AVG 5YR AVG
EPS 15.63% -42.66% -10.69%
Revenue -25.00% N/A N/A
Net Income 13.61% -60.15% -29.27%
Cash Flow 123.03% -50.75% -23.88%

Health (32%)

Company Industry
Current Ratio (TTM) 9.74 5.66
Quick Ratio (TTM) 9.74 5.44
D/E Ratio (TTM) N/A 1.19
Interest Coverage (TTM) -28.18 -5.92
Piotroski F-Score 3 5
Altman Z-Score N/A 13.21
LTL to 5YR AVG FCF -0.04 0.09
Shares Outstanding Growth 5YR AVG 20.32% 39.51%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙